Resumen de acción MEOB.F Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Mesoblast Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Mesoblast Precios históricos de las acciones Precio actual de la acción AU$1.73 Máximo en las últimas 52 semanas AU$1.91 Mínimo de 52 semanas AU$0.17 Beta 2.31 Cambio en 1 mes 64.76% Variación en 3 meses n/a Cambio de 1 año 1,630.00% Variación en 3 años 82.11% Variación en 5 años 30.08% Variación desde la OPV 54.46%
Noticias y actualizaciones recientes Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 1.511944 million. Dec 21
Mesoblast Limited’s RYONCIL® is the First U.S. FDA-Approves Mesenchymal Stromal Cell (MSC) Therapy Dec 19
FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease Dec 05
Mesoblast Limited Announces Publication in the November 2024 Online Issue of the European Journal of Heart Failure Dec 03
Mesoblast Limited, Annual General Meeting, Nov 15, 2024 Oct 17
Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil® Jul 24 Ver más actualizaciones Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 1.511944 million. Dec 21
Mesoblast Limited’s RYONCIL® is the First U.S. FDA-Approves Mesenchymal Stromal Cell (MSC) Therapy Dec 19
FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease Dec 05
Mesoblast Limited Announces Publication in the November 2024 Online Issue of the European Journal of Heart Failure Dec 03
Mesoblast Limited, Annual General Meeting, Nov 15, 2024 Oct 17
Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil® Jul 24
Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain Jul 22
Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD Jul 10
Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week Jul 01
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease Mar 27 Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million. Mar 23
Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million. Mar 14
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device Mar 11
United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease Jan 19
Mesoblast Limited, Annual General Meeting, Nov 28, 2023 Oct 30
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee Sep 27
Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease Sep 22
Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children Aug 04
Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role Jun 05
Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy Feb 17
Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain Feb 09
Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD) Feb 01
Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease Nov 23
Mesoblast Limited, Annual General Meeting, Nov 23, 2022 Oct 25
Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD Oct 04
Mesoblast Limited Announces Board Changes Aug 18
Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events Jul 19
Mesoblast Limited Provides Litigation Update Jun 18
Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L May 31
Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia May 24
Mesoblast Limited Announces Executive Changes Apr 07
Donal O'Dwyer Retires from the Board of Mesoblast Limited Feb 25
Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis Feb 22
Mesoblast Limited Appoints Eric Rose as Chief Medical Officer Feb 02
Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Jan 12
Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L Dec 17
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference Jul 16
Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease Jul 02
Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal May 25
Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis May 02
Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding Mar 04
Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics Feb 20
Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy Feb 11
Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference Jan 20
Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham Jan 12
Mesoblast Limited Announces Update on Covid-19 ARDS Trial Dec 19
Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure Dec 15
Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection Dec 09
Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19 Dec 03
Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG Nov 21
Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L Nov 20
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries Nov 19 The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited
Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline Nov 05
Mesoblast Limited Announces Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment Oct 13
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Mesoblast Limited Oct 10
Mesoblast Limited Announces US Food and Drug Administration Issues Complete Response Letter to its Biologics License Application Oct 06
Mesoblast Limited Announces Updates on RYONCIL Oct 03
Mesoblast Limited Receives Complete Response Letter from US Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children Oct 02
Mesoblast Limited Auditor Raises 'Going Concern' Doubt Aug 29
Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.33959 million. Aug 11 Rentabilidad de los accionistas MEOB.F US Biotechs Mercado US 7D 68.0% -3.6% -2.4% 1Y 1,630.0% -2.6% 23.4%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: MEOB.F superó a la industria US Biotechs, que obtuvo un rendimiento del -2.6% el año pasado.
Rentabilidad vs. Mercado: MEOB.F superó al mercado US, que obtuvo un rendimiento del 23.4% el año pasado.
Volatilidad de los precios Is MEOB.F's price volatile compared to industry and market? MEOB.F volatility MEOB.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: El precio de las acciones de MEOB.F ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de MEOB.F en el último año.
Acerca de la empresa Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza. Su plataforma tecnológica patentada de medicina regenerativa se basa en células especializadas conocidas como células de linaje mesenquimal. La empresa ofrece Remestemcel-L, que está en ensayos clínicos de fase III para el tratamiento de enfermedades inflamatorias sistémicas, como la enfermedad aguda de injerto contra huésped refractaria a esteroides y la enfermedad inflamatoria intestinal refractaria a biológicos, así como la enfermedad de Crohn; y Remestemcel-L, que está en ensayos clínicos de fase III para tratar la insuficiencia cardiaca crónica y el dolor lumbar crónico debido a la enfermedad degenerativa del disco.
Mostrar más Resumen de fundamentos de Mesoblast Limited ¿Cómo se comparan los beneficios e ingresos de Mesoblast con su capitalización de mercado? Estadísticas fundamentales de MEOB.F Capitalización bursátil US$1.73b Beneficios(TTM ) -US$87.96m Ingresos (TTM ) US$5.90m
292.7x Ratio precio-ventas (PS)
-19.6x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de MEOB.F Ingresos US$5.90m Coste de los ingresos US$41.07m Beneficio bruto -US$35.17m Otros gastos US$52.79m Beneficios -US$87.96m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.077 Margen bruto -595.87% Margen de beneficio neto -1,490.27% Ratio deuda/patrimonio 23.8%
¿Cómo se ha desempeñado MEOB.F a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/22 12:49 Precio de las acciones al final del día 2024/12/19 00:00 Beneficios 2024/06/30 Ingresos anuales 2024/06/30
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Mesoblast Limited está cubierta por 25 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Dennis Hulme APP Securities Pty Ltd. Russell Wright Barclay Pearce Capital Pty Limited Stuart Roberts Bell Potter
Mostrar 22 más analistas 
